Scopus BioPharma (SCPS) Stock Price, News & Analysis

Company Overview

Scopus BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer and inflammatory diseases. The company’s research and development programs are aimed at addressing serious medical conditions with significant unmet treatment needs.

Scopus BioPharma’s lead development program has included SCB-313, an investigational antibody-based therapy designed to target Claudin 18.2, a protein expressed on certain cancer cells. The program has been evaluated for potential use in advanced solid tumors, including cancers in which Claudin 18.2 is present. As an investigational product, SCB-313 has not been established as safe or effective for any indication.

The company has historically operated as a development-stage biotechnology business serving the pharmaceutical and healthcare markets through research, clinical development and potential commercialization of its proprietary drug candidates. Publicly available information about its broader pipeline, current operations and leadership is limited, so additional details should be confirmed through the company’s regulatory filings and other official disclosures.

Key Stats

• Today's Range: $0.0004 to $0.0004
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0006
• Volume: N/A
• Average Volume: 5,393 shs
• Market Capitalization: $7.24 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/13/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SCPS
• CIK: 1772028
• Web: scopusbiopharma.com
• Phone: 212-479-2513
• Fax: N/A
• Employees: 9
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,090,000
• Free Float: 39,938,000
• Market Cap: $7.24 thousand
• Optionable: Not Optionable
• Beta: -0.27